Research outputs
2026
A phase I double-blind, placebo-controlled (Part B only), randomised trial to evaluate the safety, tolerability, and pharmacokinetics of single dose in fed state, and repeat doses of DNDI-6899 in healthy participants
Tetlow, M., Simon, F., Dumont, E., Cota, G., Lyon, R., Dixon, J., . . . Gillon, J. -Y. (2026). A phase I double-blind, placebo-controlled (Part B only), randomised trial to evaluate the safety, tolerability, and pharmacokinetics of single dose in fed state, and repeat doses of DNDI-6899 in healthy participants. Wellcome Open Research, 11, 430. doi:10.12688/wellcomeopenres.26924.1
A randomized controlled Phase I de-escalation trial of molnupiravir and nirmatrelvir/ritonavir combination for mild-moderate SARS-CoV-2 infection
Khoo, S. H., FitzGerald, R., Edwards, C. J., Ahmad, S., Saunders, G., Else, L. J., . . . Griffiths, G. (2026). A randomized controlled Phase I de-escalation trial of molnupiravir and nirmatrelvir/ritonavir combination for mild-moderate SARS-CoV-2 infection. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 81(7), 10 pages. doi:10.1093/jac/dkag180
Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID-19: A Dose-Escalating, Randomized Controlled Phase Ib Study
Rowland, T., Fitzgerald, R., Challenger, E., Dickinson, L., Else, L. J., Walker, L., . . . Fletcher, T. E. (2026). Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID-19: A Dose-Escalating, Randomized Controlled Phase Ib Study. CLINICAL PHARMACOLOGY & THERAPEUTICS, 119(6), 1650-1661. doi:10.1002/cpt.70261
Pre-exposure prophylaxis use in blood donors in England
Debrah, J., Reynolds, C., Maddox, V., Secret, S., Baklan, H., Amara, A., . . . Harvala, H. (2026). Pre-exposure prophylaxis use in blood donors in England. Vox Sanguinis, 121(6), 770-778. doi:10.1111/vox.70232
PKRxiv: A Best Practice Model for Advancing Pharmacoequity Through Open Pharmacokinetic Data Sharing
Atoyebi, S., Venkatasubramanian, P., Akinloye, A., Eniayewu, O., Best, B. M., Else, L., & Olagunju, A. (2026). PKRxiv: A Best Practice Model for Advancing Pharmacoequity Through Open Pharmacokinetic Data Sharing. CLINICAL PHARMACOLOGY & THERAPEUTICS, 119(5), 1235-1248. doi:10.1002/cpt.70206
The pharmacokinetics of doravirine in pregnant women living with HIV and their infants
Jennings, L., Else, L., Dickinson, L., Read, L., Choudhury, D., Monk, R., . . . Khoo, S. (2026). The pharmacokinetics of doravirine in pregnant women living with HIV and their infants. In HIV MEDICINE Vol. 27 (pp. 25-26). Retrieved from https://www.webofscience.com/
Pharmacokinetics of Dolutegravir, nucleoside analogues, and intracellular metabolites using plasma separation cards: A comparative analysis with traditional sampling methods in healthy volunteers
Thompson, B., Else, L. J., Dickinson, L., Edick, S., Zyhowski, A., Ho, K., . . . Brand, R. M. (2026). Pharmacokinetics of Dolutegravir, nucleoside analogues, and intracellular metabolites using plasma separation cards: A comparative analysis with traditional sampling methods in healthy volunteers. PLOS ONE, 21(1), 18 pages. doi:10.1371/journal.pone.0341252
A model-based comparison of dose reduction strategies for fixed-dose dolutegravir-containing regimens
Dickinson, L., Else, L., Venter, W. D. F., Boffito, M., Brand, R., Waitt, C., . . . Khoo, S. (2026). A model-based comparison of dose reduction strategies for fixed-dose dolutegravir-containing regimens. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 81(1), 8 pages. doi:10.1093/jac/dkaf445
2025
Abstracts of the 26th International Workshop on Clinical Pharmacology of HIV, Hepatitis and other Antiviral Drugs 2025, 3-4 September 2025, Amsterdam, the Netherlands.
Challenger, E., Else, L., Dickinson, L., Rowland, T., Wood, W., Hale, C., . . . Khoo, S. (2025). Abstracts of the 26th International Workshop on Clinical Pharmacology of HIV, Hepatitis and other Antiviral Drugs 2025, 3-4 September 2025, Amsterdam, the Netherlands.. British journal of clinical pharmacology, 91 Suppl 1, 22. doi:10.1002/bcp.70233
Drug interactions between probe drugs dolutegravir (DTG), midazolam (MDZ) and digoxin (DIG) with escalating doses of rifampicin (RIF): DORIS study
Dickinson, L., Singh, Y., Semakula, J., Chodacki, P., Kassim, S., Namuddu, D., . . . Khoo, S. (2025). Drug interactions between probe drugs dolutegravir (DTG), midazolam (MDZ) and digoxin (DIG) with escalating doses of rifampicin (RIF): DORIS study. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 91, 12. doi:10.1002/bcp.70214
Pharmacokinetics of nitazoxanide in plasma separation cards from patients with SARS-CoV-2: AGILE CST-3a/b
Thompson, B., Else, L., Amara, A., Reynolds, H., Lyon, R., Chiong, J., . . . Khoo, S. (2025). Pharmacokinetics of nitazoxanide in plasma separation cards from patients with SARS-CoV-2: AGILE CST-3a/b. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 91, 21-22. doi:10.1002/bcp.70232
The tear production of tecovirimat in a single hospitalized mpox patient: a pharmacokinetic analysis
Woolley, S. D., Duru, I., Pagano, L., Lester, R., Devine, K., Ahmad, S., . . . Beadsworth, M. B. J. (2025). The tear production of tecovirimat in a single hospitalized mpox patient: a pharmacokinetic analysis. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 80(5), 1455-1457. doi:10.1093/jac/dkaf071
Development of an oral regimen of unithiol for the treatment of snakebite envenoming: a phase 1 open-label dose-escalation safety trial and pharmacokinetic analysis in healthy Kenyan adults
Abouyannis, M., Nyambura, Y. K., Ngome, S., Riako, D., Musyoki, J., Muiruri, C., . . . Hamaluba, M. (2025). Development of an oral regimen of unithiol for the treatment of snakebite envenoming: a phase 1 open-label dose-escalation safety trial and pharmacokinetic analysis in healthy Kenyan adults. EBIOMEDICINE, 113, 12 pages. doi:10.1016/j.ebiom.2025.105600
2024
Gene expression of tight junctions in foreskin is not affected by HIV pre-exposure prophylaxis
Webb, E. L., Petkov, S., Yun, H., Else, L., Lebina, L., Serwanga, J., . . . Chiodi, F. (2024). Gene expression of tight junctions in foreskin is not affected by HIV pre-exposure prophylaxis. FRONTIERS IN IMMUNOLOGY, 15, 12 pages. doi:10.3389/fimmu.2024.1415475
Evaluation of pharmacokinetics of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil (TDF) in pregnant and postpartum women in South Africa: PrEP-PP PK study
Davey, D. J., Dadan, S., Bheemraj, K., Waitt, C., Khoo, S., Myer, L., . . . Orrell, C. (2024). Evaluation of pharmacokinetics of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil (TDF) in pregnant and postpartum women in South Africa: PrEP-PP PK study. ANTIVIRAL RESEARCH, 231, 10 pages. doi:10.1016/j.antiviral.2024.106014
Favipiravir pharmacokinetics in saliva, tears and nasal secretions of hospitalized COVID-19 patients following intravenous favipiravir administration
Challenger, E., Rowland, T., Else, L., Dickinson, L., Hale, C., Lyon, R., . . . Fletcher, T. (2024). Favipiravir pharmacokinetics in saliva, tears and nasal secretions of hospitalized COVID-19 patients following intravenous favipiravir administration. In BRITISH JOURNAL OF CLINICAL PHARMACOLOGY Vol. 90 (pp. 8). Retrieved from https://www.webofscience.com/
Optimal dose and safety of intravenous favipiravir in hospitalized patients with SARS-COV-2: A phase I, open-label, dose-escalating, randomized controlled study
Rowland, T., FitzGerald, R., Else, L., Challenger, E., Dickinson, L., Walker, L., . . . Fletcher, T. (2024). Optimal dose and safety of intravenous favipiravir in hospitalized patients with SARS-COV-2: A phase I, open-label, dose-escalating, randomized controlled study. In BRITISH JOURNAL OF CLINICAL PHARMACOLOGY Vol. 90 (pp. 8-9). Retrieved from https://www.webofscience.com/
Pharmacokinetics of molnupiravir and favipiravir in plasma separation cards from patients with COVID-19: Agile CST-2 and CST-6
Thompson, B., Else, L., Challenger, E., Fitzgerald, R., Reynolds, H., Dickinson, L., . . . Khoo, S. (2024). Pharmacokinetics of molnupiravir and favipiravir in plasma separation cards from patients with COVID-19: Agile CST-2 and CST-6. In BRITISH JOURNAL OF CLINICAL PHARMACOLOGY Vol. 90 (pp. 13). Retrieved from https://www.webofscience.com/
Clinical, pharmacological, and qualitative characterization of drug-drug interactions in pregnant women initiating HIV therapy in Sub-Saharan Africa.
Kiiza, D., Rostami-Hochaghan, D., Alhassan, Y., Seden, K., Reynolds, H., Kaboggoza, J. P., . . . Lamorde, M. (2024). Clinical, pharmacological, and qualitative characterization of drug-drug interactions in pregnant women initiating HIV therapy in Sub-Saharan Africa.. The Journal of antimicrobial chemotherapy, dkae232. doi:10.1093/jac/dkae232
Tenofovir, emtricitabine, lamivudine and dolutegravir concentrations in plasma and urine following drug intake cessation in a randomized controlled directly observed pharmacokinetic trial to aid point-of-care testing.
Else, L. J., Dickinson, L., Edick, S., Zyhowski, A., Ho, K., Meyn, L., . . . Brand, R. M. (2024). Tenofovir, emtricitabine, lamivudine and dolutegravir concentrations in plasma and urine following drug intake cessation in a randomized controlled directly observed pharmacokinetic trial to aid point-of-care testing.. The Journal of antimicrobial chemotherapy, 79(7), 1597-1605. doi:10.1093/jac/dkae147
A novel LC-MS/MS method for the determination of favipiravir ribofuranosyl-5'-triphosphate (T-705-RTP) in human peripheral mononuclear cells.
Challenger, E., Dilly-Penchala, S., Hale, C., Fitzgerald, R., Reynolds, H., Chiong, J., . . . Else, L. (2024). A novel LC-MS/MS method for the determination of favipiravir ribofuranosyl-5'-triphosphate (T-705-RTP) in human peripheral mononuclear cells.. Journal of pharmaceutical and biomedical analysis, 245, 116155. doi:10.1016/j.jpba.2024.116155
2023
Development and validation of an LC-MS/MS method for quantification of favipiravir in human plasma
Challenger, E., Penchala, S. D., Hale, C., Fitzgerald, R., Walker, L., Reynolds, H., . . . Else, L. (2023). Development and validation of an LC-MS/MS method for quantification of favipiravir in human plasma. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 233, 7 pages. doi:10.1016/j.jpba.2023.115436
A randomized clinical trial of on-demand oral pre-exposure prophylaxis does not modulate lymphoid/myeloid HIV target cell density in the foreskin
Rametse, C. L., Webb, E., Herrera, C., Alinde, B., Besethi, A., Motaung, B., . . . Gray, C. (2023). A randomized clinical trial of on-demand oral pre-exposure prophylaxis does not modulate lymphoid/myeloid HIV target cell density in the foreskin. AIDS, 37(11), 1651-1659. doi:10.1097/QAD.0000000000003619
Dose finding study for on-demand HIV pre-exposure prophylaxis for insertive sex in sub-Saharan Africa: results from the CHAPS open label randomised controlled trial
Herrera, C., Serwanga, J., Else, L., Limakatso, L., Opoka, D., Ssemata, A. S., . . . CHAPS. (2023). Dose finding study for on-demand HIV pre-exposure prophylaxis for insertive sex in sub-Saharan Africa: results from the CHAPS open label randomised controlled trial. EBIOMEDICINE, 93. doi:10.1016/j.ebiom.2023.104648
Application of novel plasma separation filter cards for quantification of nucleoside/nucleotide reverse transcriptase inhibitor di/triphosphates in dried blood spot using LC-MS
Thompson, B., Dilly-Penchala, S., Amara, A., Reynolds, H., Khoo, S., & Else, L. (2023). Application of novel plasma separation filter cards for quantification of nucleoside/nucleotide reverse transcriptase inhibitor di/triphosphates in dried blood spot using LC-MS. BIOANALYSIS, 15(13), 739-756. doi:10.4155/bio-2023-0057
Undeclared pre-exposure or post-exposure prophylaxis (PrEP/PEP) use among syphilis-positive blood donors, England, 2020 to 2021.
Maddox, V., Reynolds, C., Amara, A., Else, L., Brailsford, S. R., Khoo, S., & Harvala, H. (2023). Undeclared pre-exposure or post-exposure prophylaxis (PrEP/PEP) use among syphilis-positive blood donors, England, 2020 to 2021.. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 28(11). doi:10.2807/1560-7917.es.2023.28.11.2300135
2022
Short-term oral pre-exposure prophylaxis against HIV-1 modulates the transcriptome of foreskin tissue in young men in Africa
Petkov, S., Herrera, C., Else, L., Lebina, L., Opoka, D., Seiphetlo, T. B., . . . Chiodi, F. (2022). Short-term oral pre-exposure prophylaxis against HIV-1 modulates the transcriptome of foreskin tissue in young men in Africa. FRONTIERS IN IMMUNOLOGY, 13, 12 pages. doi:10.3389/fimmu.2022.1009978
72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study
Malaba, T. R., Nakatudde, I., Kintu, K., Colbers, A., Chen, T., Reynolds, H., . . . Khoo, S. (2022). 72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study. LANCET HIV, 9(8), E534-E543. doi:10.1016/S2352-3018(22)00173-4
Mobilization of systemic CCL4 following HIV pre-exposure prophylaxis in young men in Africa
Petkov, S., Herrera, C., Else, L., Mugaba, S., Namubiru, P., Odoch, G., . . . Chiodi, F. (2022). Mobilization of systemic CCL4 following HIV pre-exposure prophylaxis in young men in Africa. FRONTIERS IN IMMUNOLOGY, 13, 12 pages. doi:10.3389/fimmu.2022.965214
Pre-Clinical Evaluation of Tenofovir and Tenofovir Alafenamide for HIV-1 Pre-Exposure Prophylaxis in Foreskin Tissue
Else, L., Penchala, S. D., Pillay, A. -D., Seiphetlo, T. B., Lebina, L., Callebaut, C., . . . Herrera, C. (2022). Pre-Clinical Evaluation of Tenofovir and Tenofovir Alafenamide for HIV-1 Pre-Exposure Prophylaxis in Foreskin Tissue. PHARMACEUTICS, 14(6), 13 pages. doi:10.3390/pharmaceutics14061285
Total and Unbound Doravirine Concentrations and Viral Suppression in CSF
Tiraboschi, J., Scevola, S., Penchala, S. D., Challenger, E., Else, L., Prieto, P., . . . Podzamczer, D. (2022). Total and Unbound Doravirine Concentrations and Viral Suppression in CSF. CLINICAL INFECTIOUS DISEASES, 74(10), 1855-1858. doi:10.1093/cid/ciab835
Removal of doravirine by haemodialysis in people living with HIV with end-stage renal disease
Molto, J., Graterol, F., Curran, A., Ramos, N., Imaz, A., Sandoval, D., . . . Paredes, R. (2022). Removal of doravirine by haemodialysis in people living with HIV with end-stage renal disease. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 77(7), 1989-1991. doi:10.1093/jac/dkac126
Pharmacokinetics of ss-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection
FitzGerald, R., Dickinson, L., Else, L., Fletcher, T., Hale, C., Amara, A., . . . Khoo, S. (2022). Pharmacokinetics of ss-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. CLINICAL INFECTIOUS DISEASES. doi:10.1093/cid/ciac199
An Open Label, Adaptive, Phase 1 Trial of High-Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS-CoV-2
Walker, L. E., FitzGerald, R., Saunders, G., Lyon, R., Fisher, M., Martin, K., . . . Fletcher, T. E. (2022). An Open Label, Adaptive, Phase 1 Trial of High-Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS-CoV-2. CLINICAL PHARMACOLOGY & THERAPEUTICS, 111(3), 585-594. doi:10.1002/cpt.2463
Evidence of HIV pre-exposure or post-exposure prophylaxis (PrEP/PEP) among blood donors: a pilot study, England June 2018 to July 2019
Harvala, H., Reynolds, C., Ijaz, S., Maddox, V., Penchala, S. D., Amara, A., . . . Khoo, S. (2022). Evidence of HIV pre-exposure or post-exposure prophylaxis (PrEP/PEP) among blood donors: a pilot study, England June 2018 to July 2019. SEXUALLY TRANSMITTED INFECTIONS, 98(2), 132-135. doi:10.1136/sextrans-2021-054981
TRUE-1: Trial of Repurposed Unithiol for snakebite Envenoming phase 1 (safety, tolerability, pharmacokinetics and pharmacodynamics in healthy Kenyan adults)
Abouyannis, M., FitzGerald, R., Ngama, M., Mwangudzah, H., Nyambura, Y. K., Ngome, S., . . . Hamaluba, M. (2022). TRUE-1: Trial of Repurposed Unithiol for snakebite Envenoming phase 1 (safety, tolerability, pharmacokinetics and pharmacodynamics in healthy Kenyan adults). Wellcome Open Research, 7. doi:10.12688/wellcomeopenres.17682.1
2021
The development and validation of a novel LC-MS/MS method for the simultaneous quantification of Molnupiravir and its metabolite β-d-N4-hydroxycytidine in human plasma and saliva
Amara, A., Penchala, S. D., Else, L., Hale, C., FitzGerald, R., Walker, L., . . . Khoo, S. (2021). The development and validation of a novel LC-MS/MS method for the simultaneous quantification of Molnupiravir and its metabolite β-d-N4-hydroxycytidine in human plasma and saliva. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 206, 7 pages. doi:10.1016/j.jpba.2021.114356
Intrapulmonary Pharmacokinetics of First-line Anti-tuberculosis Drugs in Malawian Patients With Tuberculosis
McCallum, A. D., Pertinez, H. E., Else, L. J., Dilly-Penchala, S., Chirambo, A. P., Sheha, I., . . . Mwandumba, H. C. (2021). Intrapulmonary Pharmacokinetics of First-line Anti-tuberculosis Drugs in Malawian Patients With Tuberculosis. CLINICAL INFECTIOUS DISEASES, 73(9), E3365-E3373. doi:10.1093/cid/ciaa1265
An open label, adaptive, phase 1 trial of high-dose oral nitazoxanide in healthy volunteers: an antiviral candidate for SARS-CoV-2
Infant Exposure to Dolutegravir Through Placental and Breast Milk Transfer: A Population Pharmacokinetic Analysis of DolPHIN-1
Dickinson, L., Walimbwa, S., Singh, Y., Kaboggoza, J., Kintu, K., Sihlangu, M., . . . Orrell, C. (2021). Infant Exposure to Dolutegravir Through Placental and Breast Milk Transfer: A Population Pharmacokinetic Analysis of DolPHIN-1. CLINICAL INFECTIOUS DISEASES, 73(5), E1200-E1207. doi:10.1093/cid/ciaa1861
Pharmacokinetic/pharmacodynamic investigation of raltegravir with or without lamivudine in the context of HIV-1 pre-exposure prophylaxis (PrEP)
Herrera, C., Lwanga, J., Lee, M., Mantori, S., Amara, A., Else, L., . . . Fox, J. (2021). Pharmacokinetic/pharmacodynamic investigation of raltegravir with or without lamivudine in the context of HIV-1 pre-exposure prophylaxis (PrEP). JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 76(8), 2129-2136. doi:10.1093/jac/dkab136
Pharmacokinetic and pharmacodynamic study of tenofovir and tenofovir alafenamide for PrEP in foreskin tissue
Herrera, C., Else, L., Penchala, S. D., Pillay, A. -D. A., Seiphetlo, T. B., Lebina, L., . . . Khoo, S. (2021). Pharmacokinetic and pharmacodynamic study of tenofovir and tenofovir alafenamide for PrEP in foreskin tissue. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY Vol. 24 (pp. 2 pages). Retrieved from https://www.webofscience.com/
2020
Combined HIV Adolescent Prevention Study (CHAPS): comparison of HIV pre-exposure prophylaxis regimens for adolescents in sub-Saharan Africa-study protocol for a mixed-methods study including a randomised controlled trial
Nash, S., Dietrich, J., Ssemata, A. S., Herrera, C., O'Hagan, K., Else, L., . . . Fox, J. (2020). Combined HIV Adolescent Prevention Study (CHAPS): comparison of HIV pre-exposure prophylaxis regimens for adolescents in sub-Saharan Africa-study protocol for a mixed-methods study including a randomised controlled trial. TRIALS, 21(1), 11 pages. doi:10.1186/s13063-020-04760-x
Genetic influence of <i>ABCG2, UGT1A1</i> and <i>NR1I2</i> on dolutegravir plasma pharmacokinetics
Elliot, E. R., Neary, M., Else, L., Khoo, S., Moyle, G., Carr, D. F., . . . Owen, A. (2020). Genetic influence of <i>ABCG2, UGT1A1</i> and <i>NR1I2</i> on dolutegravir plasma pharmacokinetics. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 75(5), 1259-1266. doi:10.1093/jac/dkz558
Genital secretion HIV RNA shedding in HIV-positive patients on ritonavir-boosted protease inhibitor monotherapy or standard combination ART: a cross-sectional sub-study from the PIVOT Trial
Arenas-Pinto, A., Stohr, W., Khoo, S., Clarke, A., Beeching, N., Warwick, Z., . . . Paton, N. I. (2020). Genital secretion HIV RNA shedding in HIV-positive patients on ritonavir-boosted protease inhibitor monotherapy or standard combination ART: a cross-sectional sub-study from the PIVOT Trial. ANTIVIRAL THERAPY, 25(1), 55-59. doi:10.3851/IMP3340
The development and validation of a novel LC-MS/MS method for the quantification of cenicriviroc in human plasma and cerebrospinal fluid
Penchala, S. D., Alagaratnam, J., Challenger, E., Amara, A., Else, L., Winston, A., & Khoo, S. (2020). The development and validation of a novel LC-MS/MS method for the quantification of cenicriviroc in human plasma and cerebrospinal fluid. BIOMEDICAL CHROMATOGRAPHY, 34(1), 8 pages. doi:10.1002/bmc.4711
2019
A Multiple Dose Phase 1 Assessment of Rilpivirine Long Acting in a Model of Preexposure Prophylaxis Against HIV
Cranston, R. D., Dezzutti, C. S., Siegel, A., Engstrom, J., Shetler, C., Richardson-Harman, N., . . . McGowan, I. (2019). A Multiple Dose Phase 1 Assessment of Rilpivirine Long Acting in a Model of Preexposure Prophylaxis Against HIV. AIDS RESEARCH AND HUMAN RETROVIRUSES, 35(9), 794-804. doi:10.1089/aid.2018.0265
Cerebrospinal fluid exposure of cenicriviroc in HIV-positive individuals with cognitive impairment
Alagaratnam, J., Dilly-Penchala, S., Challenger, E., Else, L., Legg, K., Petersen, C., . . . Winston, A. (2019). Cerebrospinal fluid exposure of cenicriviroc in HIV-positive individuals with cognitive impairment. In BRITISH JOURNAL OF CLINICAL PHARMACOLOGY Vol. 85 (pp. 1039-1040). doi:10.1111/bcp.13878
Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers (vol 74, pg 149, 2019)
Elliot, E. R., Cerrone, M., Challenger, E., Else, L., Amara, A., Bisdomini, E., . . . Boffito, M. (2019). Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers (vol 74, pg 149, 2019). JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 74(5), 1466. doi:10.1093/jac/dky571
The role of raltegravir alone or combined with lamivudine as PrEP: a phase 2 randomised controlled clinical trial
Fox, J., Herrera, C., Lwanga, J., Lee, M., Else, L., Amara, A., . . . Dickenson, L. (2019). The role of raltegravir alone or combined with lamivudine as PrEP: a phase 2 randomised controlled clinical trial. In HIV MEDICINE Vol. 20 (pp. 5-6). Retrieved from https://www.webofscience.com/
Impact of pharmacogenetics and pregnancy on tenofovir and emtricitabine pharmacokinetics
Gini, J., Olagunju, A., Dickinson, L., Waitt, C., Neary, M., Else, L. J., . . . Khoo, S. (2019). Impact of pharmacogenetics and pregnancy on tenofovir and emtricitabine pharmacokinetics. PHARMACOGENOMICS, 20(4), 217-224. doi:10.2217/pgs-2018-0111
Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine
Walimbwa, S. I., Lamorde, M., Waitt, C., Kaboggoza, J., Else, L., Byakika-Kibwika, P., . . . Khoo, S. H. (2019). Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 63(2), 9 pages. doi:10.1128/AAC.01310-18
Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers.
Elliot, E. R., Cerrone, M., Else, L., Amara, A., Bisdomini, E., Khoo, S., . . . Boffito, M. (2019). Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers.. The Journal of antimicrobial chemotherapy, 74(1), 149-156. doi:10.1093/jac/dky384
Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study)
Waitt, C., Orrell, C., Walimbwa, S., Singh, Y., Kintu, K., Simmons, B., . . . Khoo, S. (2019). Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study). PLOS MEDICINE, 16(9), 16 pages. doi:10.1371/journal.pmed.1002895
Therapeutic drug monitoring of darunavir/ritonavir in pregnancy
Murtagh, R., Else, L. J., Kuan, K. B. K., Khoo, S. H., Jackson, V., Patel, A., . . . Lambert, J. S. (2019). Therapeutic drug monitoring of darunavir/ritonavir in pregnancy. ANTIVIRAL THERAPY, 24(3), 229-233. doi:10.3851/IMP3291
2018
Validation and clinical application of a novel LC-MS method for quantification of dolutegravir in breast milk
Gini, J., Penchala, S. D., Amara, A., Challenger, E., Egan, D., Waitt, C., . . . Else, L. J. (2018). Validation and clinical application of a novel LC-MS method for quantification of dolutegravir in breast milk. BIOANALYSIS, 10(23), 1933-1945. doi:10.4155/bio-2018-0085
Widespread use of herbal medicines by people living with human immunodeficiency virus and contamination of herbal medicines with antiretrovirals in Nigeria.
Gini, J., Amara, A., Penchala, S. D., Back, D. J., Else, L., Egan, D., . . . Khoo, S. H. (2018). Widespread use of herbal medicines by people living with human immunodeficiency virus and contamination of herbal medicines with antiretrovirals in Nigeria.. International journal of STD & AIDS, 956462418809749. doi:10.1177/0956462418809749
Novel Protocol to Compare PrEP Drugs, Dosing and Schedule Using Ex Vivo Challenge on Resected Foreskin Tissue: Protocol for the CHAPS RCT
Nash, S., Herrera, C., Serwanga, J., Ruzagira, E., O'Hagan, K., Kelly, C., . . . Fox, J. (2018). Novel Protocol to Compare PrEP Drugs, Dosing and Schedule Using Ex Vivo Challenge on Resected Foreskin Tissue: Protocol for the CHAPS RCT. In AIDS RESEARCH AND HUMAN RETROVIRUSES Vol. 34 (pp. 364). Retrieved from https://www.webofscience.com/
DolPHIN-1: Randomised controlled trial of dolutegravir (DTG)- versus efavirenz (EFV)-based therapy in mothers initiating antiretroviral treatment in late pregnancy
Orrell, C., Kintu, K., Coombs, J. A., Amara, A., Myer, L., Kaboggoza, J., . . . Lamorde, M. (2018). DolPHIN-1: Randomised controlled trial of dolutegravir (DTG)- versus efavirenz (EFV)-based therapy in mothers initiating antiretroviral treatment in late pregnancy. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY Vol. 21 (pp. 166). Retrieved from https://www.webofscience.com/
Drug Interactions Between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine
Walimbwa, S., Lamorde, M., Waitt, C., Kaboggoza, J., Else, L., Byakika-Kibwika, P., . . . Khoo, S. (2018). Drug Interactions Between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine. doi:10.1101/351684
Development, validation and utilization of a highly sensitive LC-MS/MS method for quantification of levonorgestrel released from a subdermal implant in human plasma
Cirrincione, L. R., Penchala, S. D., Scarsi, K. K., Podany, A. T., Winchester, L. C., Back, D. J., . . . Else, L. J. (2018). Development, validation and utilization of a highly sensitive LC-MS/MS method for quantification of levonorgestrel released from a subdermal implant in human plasma. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 1084, 106-112. doi:10.1016/j.jchromb.2018.03.023
ABCG2 rs2231142 and NR1I2 rs2472677 influence dolutegravir concentrations in plasma.
Elliot, E., Neary, M. G., Else, L., Khoo, S., Moyle, G., Carr, D., . . . Boffito, M. (2018). ABCG2 rs2231142 and NR1I2 rs2472677 influence dolutegravir concentrations in plasma.. In CROI. Boston, MA, USA.
Pharmacokinetics and pharmacodynamics of the nucleoside sparing dual regimen containing rilpivirine plus darunavir/ritonavir in treatment-naive HIV-1-infected individuals
Jackson, A., Else, L., Higgs, C., Karolia, Z., Khoo, S., Back, D., . . . Boffito, M. (2018). Pharmacokinetics and pharmacodynamics of the nucleoside sparing dual regimen containing rilpivirine plus darunavir/ritonavir in treatment-naive HIV-1-infected individuals. HIV CLINICAL TRIALS, 19(1), 31-37. doi:10.1080/15284336.2017.1408928
2017
Population pharmacokinetic analysis of ledipasvir in patients with decompensated cirrhosis - results from the UK Expanded Access programme.
El-Sherif, O., Pertinez, H., Irving, W., Penchala, S. D., McLauchlan, J., Foster, G. R., . . . Khoo, S. (2017). Population pharmacokinetic analysis of ledipasvir in patients with decompensated cirrhosis - results from the UK Expanded Access programme.. In HEPATOLOGY Vol. 66 (pp. 831A-832A). Retrieved from https://www.webofscience.com/
Development, validation and clinical application of a method for the simultaneous quantification of lamivudine, emtricitabine and tenofovir in dried blood and dried breast milk spots using LC-MS/MS
Waitt, C., Penchala, S. D., Olagunju, A., Amara, A., Else, L., Lamorde, M., & Khoo, S. (2017). Development, validation and clinical application of a method for the simultaneous quantification of lamivudine, emtricitabine and tenofovir in dried blood and dried breast milk spots using LC-MS/MS. Journal of Chromatography B, 1060, 300-307. doi:10.1016/j.jchromb.2017.06.012
An open-label multiple-dose phase 1 assessment of long-acting rilpivirine
McGowan, I., Dezzutti, C. S., Siegel, A., Engstrom, J., Shetler, C., Richardson-Harman, N., . . . Cranston, R. D. (2017). An open-label multiple-dose phase 1 assessment of long-acting rilpivirine. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY Vol. 20 (pp. 31). Retrieved from https://www.webofscience.com/
Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge
Elliot, E. R., Amara, A., Pagani, N., Else, L., Moyle, G., Schoolmeesters, A., . . . Boffito, M. (2017). Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 72(7), 2035-2041. doi:10.1093/jac/dkx108
Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge (vol 72, pg 2035, 2017)
Elliot, E. R., Amara, A., Pagani, N., Else, L., Moyle, G., Schoolmeesters, A., . . . Boffito, M. (2017). Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge (vol 72, pg 2035, 2017). JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 72(7), 2143. doi:10.1093/jac/dkx145
ABCG2 rs2231142 influences tenofovir concentrations in plasma and urine.
Bracchi, M., Neary, M. G., Pagani, N., Else, L., Khoo, S., Abbas, Z., . . . Boffito, M. (2017). ABCG2 rs2231142 influences tenofovir concentrations in plasma and urine.. In CROI. Seattle, WA, USA.
Comparison of Dried Blood Spots Versus Conventional Plasma Collection for the Characterization of Efavirenz Pharmacokinetics in a Large-Scale Global Clinical Trial-The ENCORE1 Study
Amara, A. B., Else, L. J., Carey, D., Khoo, S., Back, D. J., Amin, J., . . . Puls, R. L. (2017). Comparison of Dried Blood Spots Versus Conventional Plasma Collection for the Characterization of Efavirenz Pharmacokinetics in a Large-Scale Global Clinical Trial-The ENCORE1 Study. THERAPEUTIC DRUG MONITORING, 39(6), 654-658. doi:10.1097/FTD.0000000000000448
2016
Discordant CSF/plasma HIV-1 RNA in patients with unexplained low-level viraemia
Nightingale, S., Geretti, A. M., Beloukas, A., Fisher, M., Winston, A., Else, L., . . . Khoo, S. (2016). Discordant CSF/plasma HIV-1 RNA in patients with unexplained low-level viraemia. Journal of NeuroVirology, 22, 852-860. doi:10.1007/s13365-016-0448-1
Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment
McGowan, I., Dezzutti, C. S., Siegel, A., Engstrom, J., Nikiforov, A., Duffill, K., . . . Cranston, R. D. (2016). Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment. LANCET HIV, 3(12), E569-E578. doi:10.1016/S2352-3018(16)30113-8
Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis
Fox, J., Tiraboschi, J. M., Herrera, C., Else, L., Egan, D., Dickinson, L., . . . Boffito, M. (2016). Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis. Journal of Acquired Immune Deficiency Syndromes, 73(3), 252-257. doi:10.1097/QAI.0000000000001108
Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis
Fox, J., Tiraboschi, J. M., Herrera, C., Else, L., Egan, D., Dickinson, L., . . . Boffito, M. (2016). Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 73(3), 252-257. Retrieved from https://www.webofscience.com/
Population pharmacokinetics (PK) of dolutegravir (DTG) alone and following treatment switch
Dickinson, L., Bracchi, M., Elliot, E., Else, L., Khoo, S., Back, D., . . . Boffito, M. (2016). Population pharmacokinetics (PK) of dolutegravir (DTG) alone and following treatment switch. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY Vol. 19 (pp. 1 page). Retrieved from https://www.webofscience.com/
Steady-state pharmacokinetics (PK) of atazanavir/cobicistat and darunavir/cobicistat once daily over 72 hours in healthy volunteers: the importance of PK forgiveness in clinical practice
Elliot, E., Amara, A., Pagani, N., Else, L., Moyle, G., Schoolmeesters, A., . . . Boffito, M. (2016). Steady-state pharmacokinetics (PK) of atazanavir/cobicistat and darunavir/cobicistat once daily over 72 hours in healthy volunteers: the importance of PK forgiveness in clinical practice. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY Vol. 19 (pp. 1 page). Retrieved from https://www.webofscience.com/
Efavirenz and Metabolites in Cerebrospinal Fluid: Relationship with CYP2B6 c.516G -> T Genotype and Perturbed Blood-Brain Barrier Due to Tuberculous Meningitis
Nightingale, S., Chau, T. T. H., Fisher, M., Nelson, M., Winston, A., Else, L., . . . Grp, P. -V. S. (2016). Efavirenz and Metabolites in Cerebrospinal Fluid: Relationship with CYP2B6 c.516G -> T Genotype and Perturbed Blood-Brain Barrier Due to Tuberculous Meningitis. Antimicrobial Agents and Chemotherapy, 60(8), 4511-4518. doi:10.1128/AAC.00280-16
The development and application of a novel LC-MS/MS method for the measurement of Dolutegravir, Elvitegravir and Cobicistat in human plasma
Penchala, S. D., Fawcett, S., Else, L., Egan, D., Amara, A., Elliot, E., . . . Khoo, S. (2016). The development and application of a novel LC-MS/MS method for the measurement of Dolutegravir, Elvitegravir and Cobicistat in human plasma. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 1027, 174-180. doi:10.1016/j.jchromb.2016.05.040
Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naive HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study
Dickinson, L., Amin, J., Else, L., Boffito, M., Egan, D., Owen, A., . . . Puls, R. (2016). Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naive HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study. CLINICAL PHARMACOKINETICS, 55(7), 861-873. doi:10.1007/s40262-015-0360-5
Persistence of rilpivirine following single dose of long-acting injection
McGowan, I., Siegel, A., Engstrom, J., Nikiforov, A., Duffill, K., Edick, S., . . . Cranston, R. D. (2016). Persistence of rilpivirine following single dose of long-acting injection. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY Vol. 19 (pp. 2 pages). Retrieved from https://www.webofscience.com/
Distinct Pharmacodynamic Activity of Rilpivirine in Ectocervical and Colonic Explant Tissue
Dezzutti, C. S., Else, L. J., Yandura, S. E., Shetler, C., Russo, J., Back, D. J., & McGowan, I. (2016). Distinct Pharmacodynamic Activity of Rilpivirine in Ectocervical and Colonic Explant Tissue. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 60(5), 2765-2770. doi:10.1128/AAC.00167-16
Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake
Elliot, E., Amara, A., Jackson, A., Moyle, G., Else, L., Khoo, S., . . . Boffito, M. (2016). Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 71(4), 1031-1036. doi:10.1093/jac/dkv425
Single dose Maraviroc provides high drug levels in all sites; no gender differences
Tiraboschi, J., Davies, O., Fox, J., Else, L., Egan, D., Amara, A., . . . Boffito, M. (2016). Single dose Maraviroc provides high drug levels in all sites; no gender differences. HIV MEDICINE, 17, 17. Retrieved from https://www.webofscience.com/
Selection of Rilpivirine-Resistant HIV-1 in a Seroconverter From the SSAT 040 Trial Who Received the 300-mg Dose of Long-Acting Rilpivirine (TMC278LA)
Penrose, K. J., Parikh, U. M., Hamanishi, K. A., Else, L., Back, D., Boffito, M., . . . Mellors, J. W. (2016). Selection of Rilpivirine-Resistant HIV-1 in a Seroconverter From the SSAT 040 Trial Who Received the 300-mg Dose of Long-Acting Rilpivirine (TMC278LA). Journal of Infectious Diseases, 213(6), 1013-1017. doi:10.1093/infdis/jiv528
Unintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeks
Scarsi, K. K., Darin, K. M., Nakalema, S., Back, D. J., Byakika-Kibwika, P., Else, L. J., . . . Lamorde, M. (2016). Unintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeks. CLINICAL INFECTIOUS DISEASES, 62(6), 675-682. doi:10.1093/cid/civ1001
Tenofovir Disoproxil Fumarate Fails to Prevent HIV Acquisition or the Establishment of a Viral Reservoir: Two Case Reports
Fox, J., Brady, M., Alexander, H., Davies, O., Robinson, N., Pace, M., . . . Frater, J. (2016). Tenofovir Disoproxil Fumarate Fails to Prevent HIV Acquisition or the Establishment of a Viral Reservoir: Two Case Reports. INFECTIOUS DISEASES AND THERAPY, 5(1), 65-71. doi:10.1007/s40121-015-0102-x
Effect of nondisclosure of HIV status in sexual health clinics on unlinked anonymous HIV prevalence estimates in England, 2005-2009
Savage, E. J., Lowndes, C. M., Sullivan, A. K., Back, D. J., Else, L. J., Murphy, G., & Gill, O. N. (2016). Effect of nondisclosure of HIV status in sexual health clinics on unlinked anonymous HIV prevalence estimates in England, 2005-2009. AIDS, 30(1), 145-149. doi:10.1097/QAD.0000000000000868
A Validated Method for Quantification of Dolutegravir Using Ultra Performance Liquid Chromatography Coupled With UV Detection
Wang, X., Penchala, S. D., Amara, A., Else, L., McClure, M., & Boffito, M. (2016). A Validated Method for Quantification of Dolutegravir Using Ultra Performance Liquid Chromatography Coupled With UV Detection. THERAPEUTIC DRUG MONITORING, 38(3), 327-331. doi:10.1097/FTD.0000000000000286
HIV-1 CNS <i>in vitro</i> infectivity models based on clinical CSF samples
Mora-Peris, B., Winston, A., Garvey, L., Else, L. J., Shattock, R. J., & Herrera, C. (2016). HIV-1 CNS <i>in vitro</i> infectivity models based on clinical CSF samples. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 71(1), 235-243. doi:10.1093/jac/dkv326
International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK.
International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK. (2016). Journal of the International AIDS Society, 19(8(Suppl 7)), 21487. doi:10.7448/ias.19.8.21487
Oral abstracts of the 21st International AIDS Conference 18-22 July 2016, Durban, South Africa.
Oral abstracts of the 21st International AIDS Conference 18-22 July 2016, Durban, South Africa. (2016). Journal of the International AIDS Society, 19(6 Suppl 5), 21264. doi:10.7448/ias.19.6.21264
2015
Is infant exposure to antiretroviral drugs during breastfeeding quantitatively important? A systematic review and meta-analysis of pharmacokinetic studies
Waitt, C. J., Garner, P., Bonnett, L. J., Khoo, S. H., & Else, L. J. (2015). Is infant exposure to antiretroviral drugs during breastfeeding quantitatively important? A systematic review and meta-analysis of pharmacokinetic studies. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(7), 1928-1941. doi:10.1093/jac/dkv080
Single oral dose of maraviroc does not prevent ex-vivo HIV infection of rectal mucosa in HIV-1 negative human volunteers
Coll, J., Moltó, J., Boix, J., Gómez-Mora, E., Else, L., García, E., . . . Cabrera, C. (2015). Single oral dose of maraviroc does not prevent ex-vivo HIV infection of rectal mucosa in HIV-1 negative human volunteers. AIDS, 29(16), 2149-2154. doi:10.1097/QAD.0000000000000769
Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation
Dickinson, L., Yapa, H. M., Jackson, A., Moyle, G., Else, L., Amara, A., . . . Boffito, M. (2015). Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 59(10), 6080-6086. doi:10.1128/AAC.01441-15
Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spots
Olagunju, A., Amara, A., Waitt, C., Else, L., Penchala, S. D., Bolaji, O., . . . Khoo, S. (2015). Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spots. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(10), 2816-2822. doi:10.1093/jac/dkv174
Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study.
Dickinson, L., Amin, J., Else, L., Boffito, M., Egan, D., Owen, A., . . . Puls, R. (2015). Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study.. Clinical pharmacology and therapeutics, 98(4), 406-416. doi:10.1002/cpt.156
Breast Milk Pharmacokinetics of Efavirenz and Breastfed Infants' Exposure in Genetically Defined Subgroups of Mother-Infant Pairs: An Observational Study
Olagunju, A., Bolaji, O., Amara, A., Waitt, C., Else, L., Adejuyigbe, E., . . . Owen, A. (2015). Breast Milk Pharmacokinetics of Efavirenz and Breastfed Infants' Exposure in Genetically Defined Subgroups of Mother-Infant Pairs: An Observational Study. Clin Infect Dis, 61(3), 453-463. doi:10.1093/cid/civ317
Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naive HIV-Infected Patients: Results of the ENCORE1 Study
Dickinson, L., Amin, J., Else, L., Boffito, M., Egan, D., Owen, A., . . . R Puls, O. B. O. T. E. S. G. (2015). Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naive HIV-Infected Patients: Results of the ENCORE1 Study. Clin Pharmacol Ther, 98(4), 406-416.
Significant interindividual variability in Telaprevir exposure in patients undergoing anti-HCV therapy: need for "real world" PK studies to identify vulnerable populations
El-Sherif, O., Dilly, P. S., Else, L., McKiernan, S., Khoo, S., & Norris, S. (2015). Significant interindividual variability in Telaprevir exposure in patients undergoing anti-HCV therapy: need for "real world" PK studies to identify vulnerable populations. IRISH JOURNAL OF MEDICAL SCIENCE, 184, S218. Retrieved from https://www.webofscience.com/
A Validated Method for Quantification of Efavirenz in Dried Blood Spots Using High-Performance Liquid Chromatography-Mass Spectrometry
Amara, A. B., Else, L. J., Tjia, J., Olagunju, A., Puls, R. L., Khoo, S., & Back, D. J. (2015). A Validated Method for Quantification of Efavirenz in Dried Blood Spots Using High-Performance Liquid Chromatography-Mass Spectrometry. THERAPEUTIC DRUG MONITORING, 37(2), 220-228. doi:10.1097/FTD.0000000000000127
Breast milk pharmacokinetics of efavirenz and breastfed infants' exposure in genetically-defined subgroups of mother-infant pairs: an observational study.
Olagunju, A., Bolaji, O., Amara, A., Waitt, C., Else, L., Adejuyigbe, E., . . . Owen, A. (2015). Breast milk pharmacokinetics of efavirenz and breastfed infants' exposure in genetically-defined subgroups of mother-infant pairs: an observational study.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
A Phase IV HIV PrEP study reveals limited ex vivo potency of oral Maraviroc against HIV-1
Tiraboschi, J., Fox, J., Herrera, C., Olejniczak, N., Jackson, A., Boffito, M., . . . Shattock, R. (2015). A Phase IV HIV PrEP study reveals limited ex vivo potency of oral Maraviroc against HIV-1. HIV MEDICINE, 16, 3-4. Retrieved from https://www.webofscience.com/
Cerebrospinal Fluid Exposure of Efavirenz and Its Major Metabolites When Dosed at 400 mg and 600 mg Once Daily: A Randomized Controlled Trial
Winston, A., Amin, J., Clarke, A., Else, L., Amara, A., Owen, A., . . . Puls, R. (2015). Cerebrospinal Fluid Exposure of Efavirenz and Its Major Metabolites When Dosed at 400 mg and 600 mg Once Daily: A Randomized Controlled Trial. CLINICAL INFECTIOUS DISEASES, 60(7), 1026-1032. doi:10.1093/cid/ciu976
Measuring undiagnosed HIV infection among GUM clinic attendees
Logan, L., Canvin, M., Murphy, G., Njoroge, J., Gill, N., Sinka, K., & Else, L. (2015). Measuring undiagnosed HIV infection among GUM clinic attendees. In HIV MEDICINE Vol. 16 (pp. 50). Retrieved from https://www.webofscience.com/
Pharmacogenetics of Pregnancy-Induced Changes in Efavirenz Pharmacokinetics
Olagunju, A., Bolaji, O., Amara, A., Else, L., Okafor, O., Adejuyigbe, E., . . . Owen, A. (2015). Pharmacogenetics of Pregnancy-Induced Changes in Efavirenz Pharmacokinetics. CLINICAL PHARMACOLOGY & THERAPEUTICS, 97(3), 298-306. doi:10.1002/cpt.43
Pharmacogenetics of pregnancy-induced changes in efavirenz pharmacokinetics.
Olagunju, A., Bolaji, O., Amara, A., Else, L., Okafor, O., Adejuyigbe, E., . . . Owen, A. (2015). Pharmacogenetics of pregnancy-induced changes in efavirenz pharmacokinetics.. Clinical pharmacology and therapeutics, 97(3), 298-306.
A PHASE 1 STUDY TO ASSESS THE SAFETY, TOLERABILITY AND PHARMACOKINETIC PROFILE OF BOCEPREVIR AND SILDENAFIL WHEN DOSED SEPARATELY AND TOGETHER, IN HEALTHY MALE VOLUNTEERS
Mora-Peris, B., Else, L., Goldmeier, D., Mears, A., Weston, R., Graham, C., . . . Winston, A. (2015). A PHASE 1 STUDY TO ASSESS THE SAFETY, TOLERABILITY AND PHARMACOKINETIC PROFILE OF BOCEPREVIR AND SILDENAFIL WHEN DOSED SEPARATELY AND TOGETHER, IN HEALTHY MALE VOLUNTEERS. SEXUALLY TRANSMITTED INFECTIONS, 91, A78. doi:10.1136/sextrans-2015-052126.231
Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS
Olagunju, A., Bolaji, O. O., Amara, A., Waitt, C., Else, L., Soyinka, J., . . . Khoo, S. (2015). Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS. Journal of Antimicrobial Chemotherapy, 70(2), 555-561. doi:10.1093/jac/dku420
Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS
Olagunju, A., Bolaji, O. O., Amara, A., Waitt, C., Else, L., Soyinka, J., . . . Khoo, S. (2015). Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(2), 555-561. doi:10.1093/jac/dku420
Effect of intermittent rifampicin on the pharmacokinetics and safety of raltegravir
Reynolds, H. E., Chrdle, A., Egan, D., Chaponda, M., Else, L., Chiong, J., . . . Khoo, S. H. (2015). Effect of intermittent rifampicin on the pharmacokinetics and safety of raltegravir. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(2), 550-554. doi:10.1093/jac/dku376
Effect of intermittent rifampicin on the pharmacokinetics and safety of raltegravir.
Reynolds, H. E., Chrdle, A., Egan, D., Chaponda, M., Else, L., Chiong, J., . . . Khoo, S. H. (2015). Effect of intermittent rifampicin on the pharmacokinetics and safety of raltegravir.. The Journal of antimicrobial chemotherapy, 70(2), 550-554.
The pharmacokinetic profile of raltegravircontaining antiretroviral therapy in HIV-infected individuals over 60 years of age
Vera, J. H., Jackson, A., Dickinson, L., Else, L., Barber, T., Mora-Peris, B., . . . Winston, A. (2015). The pharmacokinetic profile of raltegravircontaining antiretroviral therapy in HIV-infected individuals over 60 years of age. HIV CLINICAL TRIALS, 16(1), 39-42. doi:10.1179/1528433614Z.0000000006
The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age.
Vera, J. H., Jackson, A., Dickinson, L., Else, L., Barber, T., Mora-Peris, B., . . . Winston, A. (2015). The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age.. HIV clinical trials, 16(1), 39-42.
Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adults
Lamorde, M., Walimbwa, S., Byakika-Kibwika, P., Katwere, M., Mukisa, L., Sempa, J. B., . . . Merry, C. (2015). Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adults. J Antimicrob Chemother, 70(5), 1482-1486.
Switching safely: Pharmacokinetics, efficacy and safety of switching efavirenz to maraviroc twice daily in patients on suppressive antiretroviral therapy
Waters, L., Jackson, A., Else, L., Rockwood, N., Newell, S., Back, D., . . . Boffito, M. (2015). Switching safely: Pharmacokinetics, efficacy and safety of switching efavirenz to maraviroc twice daily in patients on suppressive antiretroviral therapy. Antiviral Therapy, 20(2), 157-163. doi:10.3851/IMP2817
2014
A Phase I study to assess the safety, tolerability and pharmacokinetic profile of boceprevir and sildenafil when dosed separately and together, in healthy male volunteers
Mora-Peris, B., Else, L., Goldmeier, D., Mears, A., Weston, R., Cooke, G., . . . Winston, A. (2015). A Phase I study to assess the safety, tolerability and pharmacokinetic profile of boceprevir and sildenafil when dosed separately and together, in healthy male volunteers. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(6), 1812-1815. doi:10.1093/jac/dkv035
Darunavir pharmacokinetics throughout pregnancy and postpartum
Lambert, J., Jackson, V., Else, L., Lawless, M., McDonald, G., Le Blanc, D., . . . Khoo, S. (2014). Darunavir pharmacokinetics throughout pregnancy and postpartum. J Int AIDS Soc, 17(4 Supp), 19485.
Efavirenz- but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub-dermal contraceptive implant
Scarsi, K., Lamorde, M., Darin, K., Dilly Penchala, S., Else, L., Nakalema, S., . . . Back, D. (2014). Efavirenz- but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub-dermal contraceptive implant. J Int AIDS Soc, 17(4 Supp), 19484.
DRV concentrations and viral load in CSF in patients on DRV/r 600/100 or 800/100mg once daily plus two NRTI
Di Yacovo, S., Molto, J., Ferrer, E., Curran, A., Else, L. J., Clotet, B., . . . Podzamczer, D. (2014). DRV concentrations and viral load in CSF in patients on DRV/r 600/100 or 800/100mg once daily plus two NRTI. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 17, 201-202. doi:10.7448/IAS.17.4.19821
Darunavir pharmacokinetics throughout pregnancy and postpartum
Lambert, J., Jackson, V., Else, L., Lawless, M., McDonald, G., Le Blanc, D., . . . Khoo, S. (2014). Darunavir pharmacokinetics throughout pregnancy and postpartum. Poster session presented at the meeting of Unknown Conference. doi:10.7448/IAS.17.4.19485
Efavirenz- but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub-dermal contraceptive implant
Scarsi, K., Lamorde, M., Darin, K., Penchala, S. D., Else, L., Nakalema, S., . . . Back, D. (2014). Efavirenz- but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub-dermal contraceptive implant. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 17, 4. doi:10.7448/IAS.17.4.19484
Therapeutic drug monitoring of atazanavir/ritonavir in pregnancy
Else, L. J., Jackson, V., Brennan, M., Back, D. J., Khoo, S. H., Coulter-Smith, S., & Lambert, J. S. (2014). Therapeutic drug monitoring of atazanavir/ritonavir in pregnancy. HIV MEDICINE, 15(10), 604-610. doi:10.1111/hiv.12164
Therapeutic drug monitoring of atazanavir/ritonavir in pregnancy
Else, L., Jackson, V., Brennan, M., Back, D. J., Khoo, S. H., Coulter-Smith, S., & Lambert, J. S. (2014). Therapeutic drug monitoring of atazanavir/ritonavir in pregnancy. HIV Medicine, 15(10), 604-610. doi:10.1111/hiv.12164
Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppression
Di Yacovo, M. S., Moltó, J., Ferrer, E., Curran, A., Else, L., Gisslén, M., . . . Podzamczer, D. (2014). Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppression. Journal of Antimicrobial Chemotherapy, 70(5), 1513-1516. doi:10.1093/jac/dku558
Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adults.
Else, L., Back, D., Khoo, S. H., & Merry, C. (2015). Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adults.. The Journal of Antimicrobial Chemotherapy, 70(5), 1482-1486. doi:10.1093/jac/dku575
A Phase 1 Open Label Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Intramuscular TMC278 LA (the MWRI-01 Study)
McGowan, I., Siegel, A., Duffill, K., Shetler, C., Dezzutti, C., Richardson-Harman, N., . . . Cranston, R. D. (2014). A Phase 1 Open Label Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Intramuscular TMC278 LA (the MWRI-01 Study). In AIDS RESEARCH AND HUMAN RETROVIRUSES Vol. 30 (pp. A71). doi:10.1089/aid.2014.5131a.abstract
Selection of Rilpivirine Resistant HIV-1 in a Seroconverter on Long-acting Rilpivirine (TMC278LA) from the Lowest Dose Arm of the SSAT 040 Trial
Penrose, K. J., Parikh, U. M., Hamanishi, K. A., Panousis, C., Else, L., Back, D., . . . Mellors, J. W. (2014). Selection of Rilpivirine Resistant HIV-1 in a Seroconverter on Long-acting Rilpivirine (TMC278LA) from the Lowest Dose Arm of the SSAT 040 Trial. AIDS Research and Human Retroviruses, 30(1_suppl), a69. doi:10.1089/aid.2014.5127.abstract
No pharmacokinetic interaction between raltegravir and amlodipine: importance for co-prescribing in ageing HIV-infected individuals
Singh, G. J., Jackson, A., D'Avolio, A., Else, L., De Nicolo, A., Bonora, S., . . . Boffito, M. (2014). No pharmacokinetic interaction between raltegravir and amlodipine: importance for co-prescribing in ageing HIV-infected individuals. AIDS, 28(13), 1993-1995. doi:10.1097/QAD.0000000000000356
Do patients adherent on PREP exposed to HIV have seroconversion symptoms and falsely reactive HIV tests?
Roche, M., Youssef, E., Gilleece, Y., Mccormack, S., Richardson, D., Clarke, A., . . . Else, L. (2014). Do patients adherent on PREP exposed to HIV have seroconversion symptoms and falsely reactive HIV tests?. In HIV MEDICINE Vol. 15 (pp. 107). Retrieved from https://www.webofscience.com/
Pharmacokinetics (PK) of the co-administration of raltegravir (RAL) and amlodipine (AML) to male and female healthy volunteers
Singh, G. K. J., Jackson, A., D'Avolio, A., Else, L., Bonora, S., Di Perri, G., . . . Boffito, M. (2014). Pharmacokinetics (PK) of the co-administration of raltegravir (RAL) and amlodipine (AML) to male and female healthy volunteers. HIV MEDICINE, 15, 115. Retrieved from https://www.webofscience.com/
Raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age: a Phase 1 pharmacokinetic study
Vera, J., Jackson, A., Dickinson, L., Else, L., Barber, T., Mora-Peris, B., . . . Winston, A. (2014). Raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age: a Phase 1 pharmacokinetic study. HIV MEDICINE, 15, 116. Retrieved from https://www.webofscience.com/
A Compartmental Pharmacokinetic Evaluation of Long-Acting Rilpivirine in HIV-Negative Volunteers for Pre-Exposure Prophylaxis
Jackson, A. G. A., Else, L. J., Mesquita, P. M. M., Egan, D., Back, D. J., Karolia, Z., . . . Boffito, M. (2014). A Compartmental Pharmacokinetic Evaluation of Long-Acting Rilpivirine in HIV-Negative Volunteers for Pre-Exposure Prophylaxis. CLINICAL PHARMACOLOGY & THERAPEUTICS, 96(3), 314-323. doi:10.1038/clpt.2014.118
DRV concentrations and viral load in CSF in patients on DRV/r 600/100 or 800/100mg once daily plus two NRTI.
Di Yacovo, S., Molto, J., Ferrer, E., Curran, A., Else, L., Clotet, B., . . . Podzamczer, D. (2014). DRV concentrations and viral load in CSF in patients on DRV/r 600/100 or 800/100mg once daily plus two NRTI.. Journal of the International AIDS Society, 17(4 Supp), 19821.
Efavirenz- but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub-dermal contraceptive implant.
Scarsi, K., Lamorde, M., Darin, K., Penchala, S. D., Else, L., Nakalema, S., . . . Back, D. (2014). Efavirenz- but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub-dermal contraceptive implant.. doi:10.7448/ias.17.4.19484
Pharmacokinetics of the co-administration of boceprevir and St John's wort to male and female healthy volunteers
Jackson, A., D'Avolio, A., Moyle, G., Bonora, S., Di Perri, G., Else, L., . . . Boffito, M. (2014). Pharmacokinetics of the co-administration of boceprevir and St John's wort to male and female healthy volunteers. Journal of Antimicrobial Chemotherapy, 69(7), 1911-1915. doi:10.1093/jac/dku060
Quantification of rilpivirine in human plasma, cervicovaginal fluid, rectal fluid and genital/rectal mucosal tissues using liquid chromatography-tandem mass spectrometry
Else, L. J., Tjia, J., Jackson, A., Penchala, S. D., Egan, D., Boffito, M., . . . Back, D. J. (2014). Quantification of rilpivirine in human plasma, cervicovaginal fluid, rectal fluid and genital/rectal mucosal tissues using liquid chromatography-tandem mass spectrometry. BIOANALYSIS, 6(14), 1907-1921. doi:10.4155/BIO.14.59
Significant interindividual variability in Telaprevir exposure in patients undergoing anti-HCV therapy - need for "real world" PK studies to identify vulnerable populations
El-Sherif, O., Penchala, S. D., Else, L. J., Norris, S., & Khoo, S. H. (2014). Significant interindividual variability in Telaprevir exposure in patients undergoing anti-HCV therapy - need for "real world" PK studies to identify vulnerable populations. In HEPATOLOGY Vol. 60 (pp. 689A). Retrieved from https://www.webofscience.com/
2013
The importance of drug-drug interactions in the DAA era
Back, D., & Else, L. (2013). The importance of drug-drug interactions in the DAA era. Digestive and Liver Disease, 45(S5), S343-S348. doi:10.1016/j.dld.2013.07.008
Coadministration of atazanavir-ritonavir and zinc sulfate: Impact on hyperbilirubinemia and pharmacokinetics
Moyle, G., Else, L., Jackson, A., Back, D., Yapa, M. H., Seymour, N., . . . Boffito, M. (2013). Coadministration of atazanavir-ritonavir and zinc sulfate: Impact on hyperbilirubinemia and pharmacokinetics. Antimicrobial Agents and Chemotherapy, 57(8), 3640-3644. doi:10.1128/AAC.00357-13
Validation of an electrospray ionisation LC-MS/MS method for quantitative analysis of telaprevir and its R-diastereomer
Penchala, S. D., Tjia, J., El Sherif, O., Back, D. J., Khoo, S. H., & Else, L. J. (2013). Validation of an electrospray ionisation LC-MS/MS method for quantitative analysis of telaprevir and its R-diastereomer. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 932, 100-110. doi:10.1016/j.jchromb.2013.06.013
Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in hiv-infected subjects
Mora-Peris, B., Croucher, A., Else, L. J., Vera, J. H., Khoo, S., Scullard, G., . . . Winston, A. (2013). Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in hiv-infected subjects. Journal of Antimicrobial Chemotherapy, 68(6), 1348-1353. doi:10.1093/jac/dkt006
Pharmacokinetic interaction of maraviroc with tacrolimus in a patient coinfected with HIV and hepatitis B virus following hepatic transplant due to hepatocellular carcinoma
Dufty, N. E., Gilleran, G., Hawkins, D., Else, L. J., & Taylor, S. (2013). Pharmacokinetic interaction of maraviroc with tacrolimus in a patient coinfected with HIV and hepatitis B virus following hepatic transplant due to hepatocellular carcinoma. Journal of Antimicrobial Chemotherapy, 68(4), 972-974. doi:10.1093/jac/dks486
2012
Development and validation of a LC‐MS/MS assay to quantify intracellular tenofovir‐diphosphate (TFV‐DP) and emtricitabine‐triphosphate (FTC‐TP)
Watson, V., Else, L., Tjia, J., Khoo, S., & Back, D. (2012). Development and validation of a LC‐MS/MS assay to quantify intracellular tenofovir‐diphosphate (TFV‐DP) and emtricitabine‐triphosphate (FTC‐TP). Journal of the International AIDS Society, 15(S4), 1. doi:10.7448/ias.15.6.18336
Pharmacokinetic profile of maraviroc 150 mg dosed with darunavir/ritonavir once daily, with and without nucleoside analogues, in HIV‐infected subjects
Mora‐Peris, B., Croucher, A., Else, L., Khoo, S., Vera, J., Back, D., & Winston, A. (2012). Pharmacokinetic profile of maraviroc 150 mg dosed with darunavir/ritonavir once daily, with and without nucleoside analogues, in HIV‐infected subjects. Journal of the International AIDS Society, 15(S4), 1-2. doi:10.7448/ias.15.6.18332
The effect of zinc sulphate supplementation on atazanavir/ritonavir‐associated hyperbilirubinemia
Jackson, A., Else, L., Back, D., Yapa, M., Seymour, N., Ringner‐Nackter, L., . . . Moyle, G. (2012). The effect of zinc sulphate supplementation on atazanavir/ritonavir‐associated hyperbilirubinemia. Journal of the International AIDS Society, 15(S4), 1. doi:10.7448/ias.15.6.18305
Therapeutic drug monitoring (TDM) of atazanavir in pregnancy
Else, L., Jackson, V., Brennan, M., Breiden, J., Lawless, M., Smith, S. C., . . . Lambert, J. (2012). Therapeutic drug monitoring (TDM) of atazanavir in pregnancy. Journal of the International AIDS Society, 15(S4), 1. doi:10.7448/ias.15.6.18330
Development and validation of a LC-MS/MS assay to quantify 10 anti-retroviral (ARV) drugs in cerebral spinal fluid (CSF)
Watson, V., Tjia, J., Szwandt, S., Else, L., Khoo, S., & Back, D. (2012). Development and validation of a LC-MS/MS assay to quantify 10 anti-retroviral (ARV) drugs in cerebral spinal fluid (CSF). Poster session presented at the meeting of 13th International Workshop on Clinical Pharmacology of HIV Therapy. Barcelona, Spain.
Pharmacokinetics of Lamivudine and Lamivudine-Triphosphate after Administration of 300 Milligrams and 150 Milligrams Once Daily to Healthy Volunteers: Results of the ENCORE 2 Study
Else, L. J., Jackson, A., Puls, R., Hill, A., Fahey, P., Lin, E., . . . Boffito, M. (2012). Pharmacokinetics of Lamivudine and Lamivudine-Triphosphate after Administration of 300 Milligrams and 150 Milligrams Once Daily to Healthy Volunteers: Results of the ENCORE 2 Study. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(3), 1427-1433. doi:10.1128/AAC.05599-11
Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study
Else, L., Jackson, A., Puls, R., Hill, A., Fahey, P., Lin, E., . . . Boffito, M. (2012). Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study. Antimicrobial Agents and Chemotherapy, 56(3), 1427-1433.
Improved Oral Bioavailability of Lopinavir in Melt-Extruded Tablet Formulation Reduces Impact of Third Trimester on Lopinavir Plasma Concentrations
Else, L. J., Douglas, M., Dickinson, L., Back, D. J., Khoo, S. H., & Taylor, G. P. (2012). Improved Oral Bioavailability of Lopinavir in Melt-Extruded Tablet Formulation Reduces Impact of Third Trimester on Lopinavir Plasma Concentrations. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(2), 816-824. doi:10.1128/AAC.05186-11
Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations.
Else, L., Douglas, M., Dickinson, L., Back, D. J., Khoo, S. H., & Taylor, G. P. (2012). Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations.. Antimicrobial agents and chemotherapy, 56(2), 816-824.
Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations.
Else, L., Douglas, M., Dickinson, L., Back, D., Khoo, S., & Taylor, G. P. (2012). Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations.. Antimicrobial agents and chemotherapy, 56(2), 816-824.
Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study
Else, L., Jackson, A., Puls, R., Hill, A., Fahey, P., Lin, E., . . . Boffito, M. (2012). Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study. Antimicrob Agents Chemother, 56(3), 1427-1433.
Pharmacokinetics of plasma lamivudine (3TC) and its active intracellular anabolite 3TC-triphosphate (3TC-TP) over a 24 hour dosing interval following administration of 3TC 300 mg and 150 mg once daily (od) to HIV-negative healthy volunteers. The ENCORE 2 Study.
Else, L., Jackson, A., Puls, R., Hill, A., Fahey, P., Lin, E., . . . Boffito, M. (2012). Pharmacokinetics of plasma lamivudine (3TC) and its active intracellular anabolite 3TC-triphosphate (3TC-TP) over a 24 hour dosing interval following administration of 3TC 300 mg and 150 mg once daily (od) to HIV-negative healthy volunteers. The ENCORE 2 Study.. Antimicrob Agents Chemother.
co-author
Jackson, A., Else, L., Tjia, J., Seymour, N., Stafford, M., Back, D., . . . Boffito, M. (2012). co-author. In 19th Conference on Retroviruses and Opportunistic Infections (pp. Paper #35). Seattle: CROI.
2011
Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid)
Else, L. J., Taylor, S., Back, D. J., & Khoo, S. H. (2011). Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid). ANTIVIRAL THERAPY, 16(8), 1139-1147. doi:10.3851/IMP1918
Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract
Else, L. J., Taylor, S., Back, D. J., & Khoo, S. H. (2011). Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract. ANTIVIRAL THERAPY, 16(8), 1149-1167. doi:10.3851/IMP1919
Pharmacokinetics of Antiretroviral Drugs in Anatomical Sanctuary Sites: The Male and Female Genital Tract
Else, L. J., Taylor, S., Back, D. J., & Khoo, S. H. (2011). Pharmacokinetics of Antiretroviral Drugs in Anatomical Sanctuary Sites: The Male and Female Genital Tract. Antiviral Therapy, 16(8), 1149-1167. doi:10.3851/imp1919
Sequential Population Pharmacokinetic Modeling of Lopinavir and Ritonavir in Healthy Volunteers and Assessment of Different Dosing Strategies
Dickinson, L., Boffito, M., Back, D., Else, L., von Hentig, N., Davies, G., . . . Aarons, L. (2011). Sequential Population Pharmacokinetic Modeling of Lopinavir and Ritonavir in Healthy Volunteers and Assessment of Different Dosing Strategies. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55(6), 2775-2782. doi:10.1128/AAC.00887-10
Sequential population pharmacokinetic modeling of lopinavir and ritonavir in healthy volunteers and assessment of different dosing strategies.
Dickinson, L., Boffito, M., Back, D., Else, L., von Hentig, N., Davies, G., . . . Aarons, L. (2011). Sequential population pharmacokinetic modeling of lopinavir and ritonavir in healthy volunteers and assessment of different dosing strategies.. Antimicrobial agents and chemotherapy, 55(6), 2775-2782.
Total and unbound lopinavir concentrations in the female genital tract of HIV-1 infected women during pregnancy
Else, L. J., Lyons, F., O'Shea, S., Costello, S., Mullen, J., Lechelt, M., . . . de Ruiter, A. (2011). Total and unbound lopinavir concentrations in the female genital tract of HIV-1 infected women during pregnancy. AIDS, 25(5), 722-725. doi:10.1097/QAD.0b013e3283445700
Total and unbound lopinavir concentrations in the female genital tract of HIV-1 infected women during pregnancy.
Else, L., Lyons, F., O'shea, S., Costello, S., Mullen, J., Lechelt, M., . . . de Ruiter, A. (2011). Total and unbound lopinavir concentrations in the female genital tract of HIV-1 infected women during pregnancy.. AIDS, 25(5), 722-725.
Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers
Jackson, A., Hill, A., Puls, R., Else, L., Amin, J., Back, D., . . . Boffito, M. (2011). Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers. Journal of Antimicrobial Chemotherapy, 66(3), 635-640. doi:10.1093/jac/dkq468
Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy
Lambert, J. S., Else, L. J., Jackson, V., Breiden, J., Gibbons, S., Dickinson, L., . . . Khoo, S. H. (2011). Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy. HIV Medicine, 12(3), 166-173. doi:10.1111/j.1468-1293.2010.00865.x
Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy
Lambert, J. S., Else, L. J., Jackson, V., Breiden, J., Gibbons, S., Dickinson, L., . . . Khoo, S. H. (2011). Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy. HIV MEDICINE, 12(3), 166-173. doi:10.1111/j.1468-1293.2010.00865.x
Pharmacokinetics of plasma lamivudine (3TC) and its active intracellular anabolite 3TC-triphosphate (3TC-TP) over a 24 hour dosing interval following administration of 3TC 300 mg and 150 mg once daily (od) to HIV-negative healthy volunteers. The ENCORE 2 Study.
Else, L., Jackson, A., Puls, R., Hill, A., Fahey, P., Lin, E., . . . Boffito, M. (2011). Pharmacokinetics of plasma lamivudine (3TC) and its active intracellular anabolite 3TC-triphosphate (3TC-TP) over a 24 hour dosing interval following administration of 3TC 300 mg and 150 mg once daily (od) to HIV-negative healthy volunteers. The ENCORE 2 Study.. In 12th International Workshop on Clinical Pharmacology of HIV Therapy (pp. oral communication). Miami: Virology Education.
Saliva Nevirapine (NVP) Concentrations as an Alternative Biofluid for NVP Pharmacokinetics (PK) in HIV-infected Children.
Else, L., Sabo, J., Yong, C., Macgregor, T. R., Eaton, S., Rinck, G., . . . Back, D. J. (2011). Saliva Nevirapine (NVP) Concentrations as an Alternative Biofluid for NVP Pharmacokinetics (PK) in HIV-infected Children.. In 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (pp. A1-A1164). Chicago: American Society for Microbiology.
Sequential population modelling of lopinavir and ritonavir in healthy volunteers and assessment of different doing strategies
Dickinson, L., Boffito, M., Back, D., Else, L., von Hentig, N., Davies, G., . . . Aarons, L. (2011). Sequential population modelling of lopinavir and ritonavir in healthy volunteers and assessment of different doing strategies. Antimicrob Agents Chemother, 55(6), 2775-2782.
2010
Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100, 200/150, and 200/50 mg twice daily in HIV‐negative volunteers
Jackson, A., Hill, A., Else, L., Back, D., Morley, R., Puls, R., . . . Boffito, M. (2010). Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100, 200/150, and 200/50 mg twice daily in HIV‐negative volunteers. Journal of the International AIDS Society, 13(Suppl 4), p180. doi:10.1186/1758-2652-13-s4-p180
The use of a darunavir/ritonavir once‐daily regimen in two pregnant women
Lambert, J., Else, L., Jackson, V., Dickinson, L., Back, D., Brennan, M., . . . Khoo, S. (2010). The use of a darunavir/ritonavir once‐daily regimen in two pregnant women. Journal of the International AIDS Society, 13(Suppl 4), p189. doi:10.1186/1758-2652-13-s4-p189
Therapeutic drug monitoring (TDM) of atazanavir in pregnancy
Else, L., Jackson, V., Brennan, M., Breiden, J., Weldridge, C., Coulter‐Smith, S., . . . Lambert, J. (2010). Therapeutic drug monitoring (TDM) of atazanavir in pregnancy. Journal of the International AIDS Society, 13(Suppl 4), p177. doi:10.1186/1758-2652-13-s4-p177
Darunavir concentrations exceed the protein-corrected EC<sub>50</sub> for wild-type HIV in the semen of HIV-1-infected men
Taylor, S., Jayasuriya, A. N., Berry, A., Gilleran, G., Dufty, N. E., Else, L., . . . Smit, E. J. (2010). Darunavir concentrations exceed the protein-corrected EC<sub>50</sub> for wild-type HIV in the semen of HIV-1-infected men. AIDS, 24(16), 2574-2577. doi:10.1097/QAD.0b013e32833ead18
Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds
Else, L., Watson, V., Tjia, J., Hughes, A., Siccardi, M., Khoo, S., & Back, D. (2010). Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 878(19), 1455-1465. doi:10.1016/j.jchromb.2010.03.036
Evaluating the affect of gender on darunavir and ritonavir (DRV/r) exposure in HIV infected subjects (a post-hoc analysis of the GRACE PK sub-study).
Else, L., Liptrott, N., Moss, D., Dutton, J., Fraser, W., Kakuda, T., . . . Back, D. (2010). Evaluating the affect of gender on darunavir and ritonavir (DRV/r) exposure in HIV infected subjects (a post-hoc analysis of the GRACE PK sub-study).. In 11th International Workshop on Clinical Pharmacology of HIV Therapy. (pp. P19). Sorrento: Virology Education.
Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers.
Jackson, A., Hill, A., Puls, R., Else, L., Amin, J., Back, D., . . . Boffito, M. (2010). Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers.. J Antimicrob Chemother..
Raltegravir (RAL) in combination with etravirine (ETV) - is there a case for therapeutic drug monitoring (TDM) in clinical practice?
Leake Date, H., Else, L., Dosekun, O., Back, D., Nathan, B., Kulasegaram, R., & Aboud, M. (2010). Raltegravir (RAL) in combination with etravirine (ETV) - is there a case for therapeutic drug monitoring (TDM) in clinical practice?. In Second Joint Conference of the British HIV Association (BHIVA) with the British Association for Sexual Health and HIV (BASHH). (pp. P6). Manchester: BHIVA.
Therapeutic drug monitoring (TDM) of lopinavir/ritonavir (LPV/r) in pregnancy.
Else, L., Lambert, J. S., Jackson, V., Breiden, J., Gibbons, S., Dickinson, L., . . . Khoo, S. (2010). Therapeutic drug monitoring (TDM) of lopinavir/ritonavir (LPV/r) in pregnancy.. In Second Joint Conference of the British HIV Association (BHIVA) with the British Association for Sexual Health and HIV (BASHH). (pp. P12). Manchester: HIV Med.
Therapeutic drug monitoring of lopinavir in pregnancy.
Lambert, J. S., Else, L., Jackson, V., Breiden, J., Gibbons, S., Dickinson, L., . . . Khoo, S. H. (2010). Therapeutic drug monitoring of lopinavir in pregnancy.. HIV Med. doi:10.1111/j.1468-1293.2010.00865.x
Total and unbound lopinavir/ritonavir (LPV/r) concentrations in the genital tract (fGT) of HIV-1 infected women during pregnancy.
Lyons, F., Else, L., O'Shea, S., Costello, S., Mullen, J., Lechelt, M., . . . de Ruiter, A. (2010). Total and unbound lopinavir/ritonavir (LPV/r) concentrations in the genital tract (fGT) of HIV-1 infected women during pregnancy.. In Second Joint Conference of the British HIV Association (BHIVA) with the British Association for Sexual Health and HIV (BASHH) (pp. P9). Manchester: BHIVA.
Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds.
Else, L., Watson, V., Tjia, J., Hughes, A., Siccardi, M., Khoo, S., & Back, D. J. (2010). Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds.. Chromatogr B Analyt Technol Biomed Life Sci., 878(19), 1455-1465.
2009
Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patients.
Yilmaz, A., Watson, V., Else, L., & Gisslèn, M. (2009). Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patients.. AIDS (London, England), 23(18), 2537-2540. doi:10.1097/qad.0b013e328333ae0e
Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tablets
Pollock, L., Else, L., Poerksen, G., Molyneux, E., Moons, P., Walker, S., . . . Khoo, S. (2009). Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tablets. Journal of Antimicrobial Chemotherapy, 64(6), 1251-1259. doi:10.1093/jac/dkp358
Validation of an ultra-sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for simultaneous determination of 11 anti-retroviral compounds
Else, L., Watson, V., Tjia, J., Siccardi, M., Khoo, S., & Back, D. (2009). Validation of an ultra-sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for simultaneous determination of 11 anti-retroviral compounds. In BRITISH JOURNAL OF CLINICAL PHARMACOLOGY Vol. 68 (pp. 276). Retrieved from https://www.webofscience.com/
Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers.
Dickinson, L., Boffito, M., Back, D., Waters, L., Else, L., Davies, G., . . . Aarons, L. (2009). Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers.. The Journal of antimicrobial chemotherapy, 63(6), 1233-1243.
Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers
Dickinson, L., Boffito, M., Back, D., Waters, L., Else, L., Davies, G., . . . Aarons, L. (2009). Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 63(6), 1233-1243. doi:10.1093/jac/dkp102
Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patients.
Yilmaz, A., Watson, V., Else, L., & Gissien, M. (2009). Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patients.. AIDS, 23(18), 2537-2540.
Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tablets.
Pollock, L., Else, L., Poerksen, G., Molyneux, E., Moons, P., Walker, S., . . . Khoo, S. (2009). Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tablets.. J Antimicrob Chemother., 64(6), 1251-1259.
The role of pharmacokinetics in optimising antiretroviral therapy in HIV-infected patients
Else, L. (2009). The role of pharmacokinetics in optimising antiretroviral therapy in HIV-infected patients. (PhD Thesis, University of Liverpool).
2008
Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation
Boffito, M., Else, L., Back, D., Taylor, J., Khoo, S., Sousa, M., . . . Moyle, G. (2008). Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation. Antiviral Therapy, 13(7), 901-907.
Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients
Moltó, J., Santos, J. R., Pérez-Álvarez, N., Cedeño, S., Miranda, C., Khoo, S., . . . Clotet, B. (2008). Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients. Antimicrobial Agents and Chemotherapy, 52(11), 3928-3932. doi:10.1128/AAC.00520-08
Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients.
Moltó, J., Santos, J. R., Pérez-Alvarez, N., Cedeño, S., Miranda, C., Khoo, S., . . . Clotet, B. (2008). Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients.. Antimicrobial agents and chemotherapy, 52(11), 3928-3932.
A study to evaluate the efficacy, safety and tolerability of co-administered lopinavir/ritonavir (LPVr) and nevirapine (NVP) in HIV-infected adults
Mahungu, T., Else, L., Smith, C., Cuthbertson, Z., Podlekareva, D., Hay, P., . . . Youle, M. (2008). A study to evaluate the efficacy, safety and tolerability of co-administered lopinavir/ritonavir (LPVr) and nevirapine (NVP) in HIV-infected adults. Journal of the International AIDS Society, 11(Suppl 1), p6. doi:10.1186/1758-2652-11-s1-p6
An open-label multicentre pilot study evaluating the pharmacokinetics (PK) of co-administered lopinavir (LPV) and nevirapine (NVP) in HIV+ adults
Else, L., Mahungu, T., Cuthbertson, Z., Smith, C., Podlekareva, D., Hay, P., . . . Youle, M. (2008). An open-label multicentre pilot study evaluating the pharmacokinetics (PK) of co-administered lopinavir (LPV) and nevirapine (NVP) in HIV+ adults. Journal of the International AIDS Society, 11(Suppl 1), p250. doi:10.1186/1758-2652-11-s1-p250
Modelling the change in lopinavir apparent oral clearance over time following cessation of lopinavir/ritonavir: data from the TAIL study
Dickinson, L., Boffito, M., Else, L., Moyle, G., Khoo, S., Pozniak, A., & Aarons, L. (2008). Modelling the change in lopinavir apparent oral clearance over time following cessation of lopinavir/ritonavir: data from the TAIL study. In Journal of the International AIDS Society Vol. 11 (pp. p241). Wiley. doi:10.1186/1758-2652-11-s1-p241
Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation
Back, D., Else, L., Khoo, S., Boffito, M., Taylor, J., Sousa, M., . . . Moyle, G. (2008). Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation. ANTIVIRAL THERAPY, 13(7), 901-907.
Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation.
Boffito, M., Else, L., Back, D., Taylor, J., Khoo, S., Sousa, M., . . . Moyle, G. (2008). Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation.. Antiviral therapy, 13(7), 901-907.
Therapeutic Drug Monitoring of new formulation Kaletra in pregnancy
Else, L., Jackson, V., Khoo, S., Gibbons, S., Brennan, M., O Connor, E., . . . Lambert, J. S. (2008). Therapeutic Drug Monitoring of new formulation Kaletra in pregnancy. In The 9th International Congress on Drug Therapy in HIV Infection Vol. 11 (pp. P119). Glasgow: Journal of the International AIDS Society.
Therapeutic drug monitoring of atazanavir in pregnancy
Lambert, J., Else, L., Jackson, V., Gibbons, S., Brennan, M., Kieran, J., . . . Khoo, S. (2008). Therapeutic drug monitoring of atazanavir in pregnancy. Journal of the International AIDS Society, 11(Suppl 1), p246. doi:10.1186/1758-2652-11-s1-p246
Therapeutic drug monitoring of new formulation Kaletra in pregnancy
Jackson, V., Else, L., Khoo, S., Gibbons, S., Brennan, M., Connor, E., . . . Lambert, J. (2008). Therapeutic drug monitoring of new formulation Kaletra in pregnancy. Journal of the International AIDS Society, 11(Suppl 1), p199. doi:10.1186/1758-2652-11-s1-p199
Total and unbound nevirapine (NVP) pharmacokinetics (PK) in HIV-infected children treated with divided fixed-dose combination (FDC) tablets in Malawi.
Else, L., Pollock, L., Poerkson, G., Back, D. J., Khoo, S. H., Fraser, W., . . . Molyneux, E. (2008). Total and unbound nevirapine (NVP) pharmacokinetics (PK) in HIV-infected children treated with divided fixed-dose combination (FDC) tablets in Malawi.. In 9th International Workshop on Clinical Pharmacology of HIV Therapy (pp. O7). New Orleans: Virology Education.
Validation of an ultra-sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for simultaneous determination of 11 anti-retroviral compounds.
Else, L., Watson, V., Tjia, J., Siccardi, M., Khoo, S. H., & Back, D. J. (2008). Validation of an ultra-sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for simultaneous determination of 11 anti-retroviral compounds.. In British Pharmacological Society Winter Meeting (pp. n/a). Brighton: British Pharmacological Society, 16 Angel Gate, City Road, London, UK.
2007
Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients
Waters, L. J., Moyle, G., Bonora, S., D'Avolio, A., Else, L., Mandalia, S., . . . Boffito, M. (2007). Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients. Antiviral Therapy, 12(5), 825-830. doi:10.1177/135965350701200510
Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
Waters, L. J., Moyle, G., Bonora, S., D'Avolio, A., Else, L., Mandalia, S., . . . Boffito, M. (2007). Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.. Antiviral therapy, 12(5), 825-830.
2006
Strategies to aid pharmacokinetic studies of antiretrovirals in developing countries
Dickinson, L., Hamdulay, N. S., Else, L. J., Khoo, S. H., & Back, D. J. (2006). Strategies to aid pharmacokinetic studies of antiretrovirals in developing countries. In DRUG METABOLISM REVIEWS Vol. 38 (pp. 33-34). Retrieved from https://www.webofscience.com/
Strategies to aid pharmacokinetic studies of antiretrovirals in developing countries
Dickinson, L., Hamdulay, N. S., Else, L. J., Khoo, S. H., & Back, D. J. (2006). Strategies to aid pharmacokinetic studies of antiretrovirals in developing countries. In DRUG METABOLISM REVIEWS Vol. 38 (pp. 73). Retrieved from https://www.webofscience.com/